Trial | NCT04606836  Report issue

Title

ICNBs for Post-op Pain in Breast Surgery
Analyzing the Efficacy of Peri-operative Intercostal Nerve Blocks ICNB for Acute Postoperative Pain Control in Reconstructive Breast Surgery and Mammoplasty

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    40
The authors will conduct this study to analyze the effectiveness of peri-operative intercostal nerve blocks (ICNBs) in reducing acute postoperative pain after reconstructive breast surgery and mammoplasty and how it affects the length of hospital stay.
Study Started
Dec 07
2020
Primary Completion
Apr 30
2021
Anticipated
Study Completion
Aug 31
2021
Anticipated
Last Update
Dec 09
2020

Drug Bupivacaine Hydrochloride

See group descriptions

  • Other names: Marcaine

Prospective Cases Experimental

These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).

Retrospective Controls No Intervention

Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.

Criteria 

Inclusion Criteria:

American Society of Anesthesiologists Classification (ASA Class) 3 and below.
Bilateral or unilateral breast surgery including cancer extirpation, reconstruction (implant and expander), oncoplastic surgery (<200 gm), breast augmentation and breast reduction, etc.

Exclusion Criteria:

Patients who refuse local anesthesia.
Patients who cannot receive local anesthesia.
Below the age of 20 and above the age of 70.
Patients requiring reoperation due to complications of mammoplasty or another breast surgery.
Poorly controlled diabetics, uncontrolled hypertension, heart disease, arrhythmias, diagnosed with bipolar and generalized anxiety disorders.
No Results Posted